ESC 365 - The tyrosine kinase inhibitor nilotinib inhibits discoidin domain receptor 2 in human aortic valves, increases aortic valve thickness and induces valvular interstitial cell calcification

ESC Premium Access

The tyrosine kinase inhibitor nilotinib inhibits discoidin domain receptor 2 in human aortic valves, increases aortic valve thickness and induces valvular interstitial cell calcification

Session: Late Breaking Basic and Translational Science - Atherosclerosis and Aortic Stenosis

Topic: Cardio-Oncology

Speaker: Professor M. Back (Stockholm, SE)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Magnus Back

Karolinska University Hospital, Stockholm (Sweden)

8 presentations

0 follower

4 more presentations in this session

Heat Shock Protein 25 Immunotherapy Post-Menopause is Superior to Estradiol in Targeting Atherogenesis, Plasma Cholesterol and PCSK9 Levels

Speaker: Professor E. O'Brien (Calgary, CA)

A novel CT-based radiotranscriptomic signature of perivascular fat improves cardiac risk prediction in the SCOT-HEART and CRISP-CT studies

Speaker: Professor C. Antoniades (Oxford, GB)

Clonal hematopoiesis of indeterminate potential (CHIP) in patients with degenerative aortic valve stenosis: incidence, clinical correlates, and prognostic significance following TAVI

Speaker: Doctor S. Mas-Peiro (Frankfurt, DE)

Dipeptidyl Peptidase-4 Inhibition to Prevent Calcific Aortic Valve Disease: Proof of Concept Study (DIP CAVD_POC)

Speaker: Doctor J. Song (Seoul, KR)

Access the full session

Late Breaking Basic and Translational Science - Atherosclerosis and Aortic Stenosis

Speakers: Professor M. Back, Professor E. O'Brien, Professor C. Antoniades, Doctor S. Mas-Peiro, Doctor J. Song

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources